Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

intervet international b.v. - lammaste katarraalse palaviku viiruse vaktsiin, serotüüp 8 (inaktiveeritud) - munarakkude immunoloogilised omadused - cattle; sheep - sheepfor aktiivse immuniseerimise lamba 2. 5-kuune vanus, et vältida viraemiat * ja vähendada lammaste katarraalse palaviku viiruse serotüüp 8 põhjustatud kliinilisi tunnuseid. cattlefor aktiivse immuniseerimise karja 2. 5 kuu vanuselt, et ennetada vereemiat *, mis on põhjustatud lammaste katarraalse palaviku viiruse serotüübist 8. * (jalgrattasuurus (ct) ≥ 36 valideeritud rt-pcr meetodil, mis viitab viiruse genoomi olemasolule).

Eesti - eesti - Ravimiamet

ge healthcare as - gadoteerhape - süstelahus - 0,5mmol 1ml 20ml 10tk

Eesti - eesti - Ravimiamet

le vet. beheer b.v. - romifidiin - süstelahus - 10mg 1ml 20ml 1tk

Eesti - eesti - Ravimiamet

vetoquinol biowet sp. z o.o. - atsepromasiin - suukaudne geel - 35mg 1ml 10ml 1tk

Eesti - eesti - Ravimiamet

laboratorios hipra s.a. - lindude nakkava bursiidi (gumboro) viirusvaktsiin - suukaudse suspensiooni lüofilisaat - 1annus 5000annus 10tk

Eesti - eesti - Ravimiamet

demo s.a. - tseftasidiim - süste-/infusioonilahuse pulber - 2000mg 1tk

Eesti - eesti - Ravimiamet

roche eesti osaühing - midasolaam - õhukese polümeerikattega tablett - 7,5mg 10tk

Eesti - eesti - Ravimiamet

chiesi pharmaceuticals gmbh - pamidroonhape - infusioonilahuse kontsentraat - 15mg 1ml 6ml 4tk; 15mg 1ml 6ml 1tk; 15mg 1ml 4ml 1tk; 15mg 1ml 2ml 4tk; 15mg 1ml 1ml 4tk; 15mg 1ml 2ml 1tk; 15mg 1ml 4ml 4tk

Eesti - eesti - Ravimiamet

nassington limited - lidokaiin+prilokaiin - kreem - 25mg+25mg 1g 30g 1tk; 25mg+25mg 1g 5g 5tk; 25mg+25mg 1g 5g 1tk